Format

Send to

Choose Destination
Clin Pharmacol Ther. 2014 May;95(5):483-5. doi: 10.1038/clpt.2014.23.

Drug development in serious diseases: the new "breakthrough therapy" designation.

Author information

1
Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

Abstract

The US Food and Drug Administration Safety and Innovation Act (FDASIA) was signed on 9 July 2012. This law created a new "breakthrough therapy" (BT) designation program for investigational drugs and biologics intended to treat a serious disease and having "preliminary clinical evidence [that] indicates that the drug may demonstrate substantial clinical improvement over existing therapies on one or more clinically significant endpoints."(1) Many questions have been posed about the impact of this new program on drug development.

PMID:
24747238
DOI:
10.1038/clpt.2014.23
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center